“The PRECISE study is a milestone for the broader field of reconstructive microsurgery,” said Mark Toland, CEO of MMI. “It reflects MMI’s commitment to building the rigorous clinical evidence needed ...
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and ScandinaviaExpands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback